| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Steviolbioside does not have a well-defined pharmacological target. As a natural sweetener, it interacts with sweet taste receptors (T1R2/T1R3). It is a terpenoid compound that is converted into antituberculotic and antibacterial agents. Steviolbioside also displays moderate antituberculosis activity against Mycobacterium tuberculosis.
|
|---|---|
| ln Vitro |
Steviolbioside shows antibacterial effects. It displays moderate antituberculosis activity against Mycobacterium tuberculosis. Steviolbioside has inhibitory effects on several human cancer cells, including Hep3B (liver), MDA-MB-231 (breast), and BxPC-3 (pancreatic) cancer cells.
|
| ln Vivo |
Specific in vivo efficacy data for steviolbioside are not extensively detailed in standard reference sources. It has been used in trials studying the treatment of HIV-1 infection. As a natural sweetener, it is consumed orally and is generally recognized as safe.
|
| Enzyme Assay |
Steviolbioside's antibacterial activity can be assessed using standard broth microdilution or agar diffusion methods. Bacterial strains are cultured in appropriate media and exposed to serial two-fold dilutions of steviolbioside. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that visibly inhibits bacterial growth.
|
| Cell Assay |
The cellular activity of steviolbioside is evaluated in cancer cell lines. Cells (e.g., Hep3B, MDA-MB-231, BxPC-3) are treated with increasing concentrations of steviolbioside. Cell viability is assessed using MTT or CellTiter-Glo assays. The compound's inhibitory effects on cancer cell proliferation are determined.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for steviolbioside are not extensively detailed in standard reference sources. For evaluating its antibacterial or anticancer activity, steviolbioside would be administered to animal models of infection or cancer. Efficacy would be assessed by measuring bacterial load, tumor growth, and survival.
|
| ADME/Pharmacokinetics |
Steviolbioside has a molecular formula of C32H50O13 and a molecular weight of 642.73. It is insoluble in ethanol and water, but soluble in DMSO at ≥42 mg/mL. Specific pharmacokinetic parameters are not extensively detailed in standard reference sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of steviolbioside is not extensively documented. As a natural sweetener derived from Stevia, it is generally considered safe for consumption. Specific LD50 values and organ-specific toxicity data are not readily available.
|
| References | |
| Additional Infomation |
Steviolbioside is a β-D-glucoside, formed by converting the 2-hydroxyl group of the glucoside moiety in steviol glycosides to β-D-glucoside. It possesses the functions of a sweetener, plant metabolite, and anti-tuberculosis drug. It is a β-D-glucoside, ent-kaurane diterpenoid, monocarboxylic acid, bridging compound, diterpenoid glycoside, and tetracyclic diterpenoid. Functionally, it is related to steviol glycosides. It is the conjugate acid of steviol glycoside (1-). Steviolbioside has been used in clinical trials for the treatment of HIV-1 infection. Steviolbioside has been discovered in stevia (Stevia rebaudiana), and relevant data have been reported. See also: Stevia rebaudiana leaf (part).
Steviolbioside (CAS# 41093-60-1) is a diterpene glycoside extracted from Stevia rebaudiana leaves. It is a natural sweetener with antibacterial and moderate antituberculosis activity. Steviolbioside has inhibitory effects on several human cancer cell lines. It has been used in trials for HIV-1 infection treatment. |
| Molecular Formula |
C32H50O13
|
|---|---|
| Molecular Weight |
642.74
|
| Exact Mass |
642.325
|
| CAS # |
41093-60-1
|
| PubChem CID |
16401639
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
847.3±65.0 °C at 760 mmHg
|
| Melting Point |
190ºC (methanol )
|
| Flash Point |
267.6±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.628
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1150
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)(C)C(=O)O
|
| InChi Key |
OMHUCGDTACNQEX-OSHKXICASA-N
|
| InChi Code |
InChI=1S/C32H50O13/c1-15-11-31-9-5-18-29(2,7-4-8-30(18,3)28(40)41)19(31)6-10-32(15,14-31)45-27-25(23(38)21(36)17(13-34)43-27)44-26-24(39)22(37)20(35)16(12-33)42-26/h16-27,33-39H,1,4-14H2,2-3H3,(H,40,41)/t16-,17-,18+,19+,20-,21-,22+,23+,24-,25-,26+,27+,29-,30-,31-,32+/m1/s1
|
| Chemical Name |
(1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
|
| Synonyms |
CCRIS 6025; CCRIS6025; CCRIS-6025
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~155.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5558 mL | 7.7792 mL | 15.5584 mL | |
| 5 mM | 0.3112 mL | 1.5558 mL | 3.1117 mL | |
| 10 mM | 0.1556 mL | 0.7779 mL | 1.5558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
